Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer
Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer
Recruiting · NCT06459687 · Registry updated 2025-05-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, cervix disorder, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Recruiting | Phase 3 | 2025-05-14 | NCT06459687 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Lee's Pharmaceutical Limited | 5 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Anhui Provincial Cancer Hospital | Hefei | China | 22 |
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing | China | 71 |
| Hunan Cancer Hospital | Changsha | China | 123 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan | China | 77 |
| Zhejiang Cancer Hospital | Hangzhou | China | 164 |